FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W101067898> ?p ?o ?g. }

• W101067898 endingPage "447" @default.
• W101067898 startingPage "447" @default.
• W101067898 abstract "Candidate cancer-targeting agents identified by expression-profiling arrays Vittavat Termglinchan,1 Wachiraporn Wanichnopparat,1 Kulachanya Suwanwongse,1 Chunhakarn Teeyapant,1 Kanticha Chatpermporn,1 Kanchana Leerunyakul,1 Khwanruthai Chuadpia,1 Onpailin Sirimaneethum,1 Parinya Wijitworawong,1 Wattanakitch Mutirangura,1 Chatchawit Aporntewan,2 Chanida Vinayanuwattikun,3 Apiwat Mutirangura4 1Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 2Department of Mathematics and Computer Science, Faculty of Science, Chulalongkorn University, Bangkok, Thailand; 3Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn Memorial Hospital, Bangkok, Thailand; 4Center of Excellence in Molecular Genetics of Cancer and Human Diseases, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Background: One particularly promising component of personalized medicine in cancer treatment is targeted therapy, which aims to maximize therapeutic efficacy while minimizing toxicity. However, the number of approved targeted agents remains limited. Expression microarray data for different types of cancer are resources to identify genes that were upregulated. The genes are candidate targets for cancer-targeting agents for future anticancer research and targeted treatments. Methods and findings: The gene expression profiles of 48 types of cancer from 2,141 microarrays reported in the Gene Expression Omnibus were analyzed. These data were organized into 78 experimental groups, on which we performed comprehensive analyses using two-tailed Student&#39;s t-tests with significance set at P < 0.01 to identify genes that were upregulated compared with normal cells in each cancer type. The resulting list of significantly upregulated genes was cross-referenced with three categories of protein inhibitor targets, categorized by inhibitor type (&#39;Targets of US Food and Drug Administration (FDA)-approved anticancer drugs&#39;, &#39;Targets of FDA-approved nonantineoplastic drugs&#39;, or &#39;Targets of non-FDA-approved chemical agents&#39;). Of the 78 experimental groups studied, 57 (73%) represent cancers that are currently treated with FDA-approved targeted treatment agents. However, the target genes for the indicated therapies are upregulated in only 33 of these groups (57%). Nevertheless, the mRNA expression of the genes targeted by FDA-approved treatment agents is increased in every experimental group, including all of the cancers without FDA-approved targeted treatments. Moreover, many targets of protein inhibitors that have been approved by the FDA as therapies for nonneoplastic diseases, such as 3-hydroxy-3-methylglutaryl-CoA reductase and cyclooxygenase-2 and the targets of many non-FDA-approved chemical agents, such as cyclin-dependent kinase 1 and DNA-dependent protein kinase, are also overexpressed in many types of cancer. Conclusion: This research demonstrates a clinical correlation between bioinformatics data and currently approved treatments and suggests novel uses for known protein inhibitors in future antineoplastic research and targeted therapies. Keywords: personalized medicine, targeted therapy, protein inhibitor, cancer treatment, upregulated gene expression" @default.
• W101067898 created "2016-06-24" @default.
• W101067898 creator A5000481700 @default.
• W101067898 creator A5011572479 @default.
• W101067898 creator A5021302353 @default.
• W101067898 creator A5036896389 @default.
• W101067898 creator A5037010363 @default.
• W101067898 creator A5040401045 @default.
• W101067898 creator A5048224285 @default.
• W101067898 creator A5048601363 @default.
• W101067898 creator A5052105775 @default.
• W101067898 creator A5054922325 @default.
• W101067898 creator A5058656430 @default.
• W101067898 creator A5072732975 @default.
• W101067898 creator A5089701217 @default.
• W101067898 date "2013-04-01" @default.
• W101067898 modified "2023-09-30" @default.
• W101067898 title "Candidate cancer-targeting agents identified by expression-profiling arrays" @default.
• W101067898 cites W1571056179 @default.
• W101067898 cites W1726054188 @default.
• W101067898 cites W1967447048 @default.
• W101067898 cites W1970005961 @default.
• W101067898 cites W1971102070 @default.
• W101067898 cites W1975165604 @default.
• W101067898 cites W1980220053 @default.
• W101067898 cites W1982248155 @default.
• W101067898 cites W1987349557 @default.
• W101067898 cites W1988584002 @default.
• W101067898 cites W1991219870 @default.
• W101067898 cites W1991429659 @default.
• W101067898 cites W1995794901 @default.
• W101067898 cites W2004463118 @default.
• W101067898 cites W2014662529 @default.
• W101067898 cites W2015015957 @default.
• W101067898 cites W2015859997 @default.
• W101067898 cites W2020541351 @default.
• W101067898 cites W2021053102 @default.
• W101067898 cites W2031162007 @default.
• W101067898 cites W2037022423 @default.
• W101067898 cites W2039045990 @default.
• W101067898 cites W2049459689 @default.
• W101067898 cites W2049659810 @default.
• W101067898 cites W2051885011 @default.
• W101067898 cites W2061383773 @default.
• W101067898 cites W2066849471 @default.
• W101067898 cites W2068370462 @default.
• W101067898 cites W2072279751 @default.
• W101067898 cites W2075674169 @default.
• W101067898 cites W2077813812 @default.
• W101067898 cites W2078523315 @default.
• W101067898 cites W2079430799 @default.
• W101067898 cites W2082472490 @default.
• W101067898 cites W2083433702 @default.
• W101067898 cites W2093313266 @default.
• W101067898 cites W2094678200 @default.
• W101067898 cites W2098775844 @default.
• W101067898 cites W2105005481 @default.
• W101067898 cites W2106599253 @default.
• W101067898 cites W2122453480 @default.
• W101067898 cites W2127496562 @default.
• W101067898 cites W2132973959 @default.
• W101067898 cites W2133105825 @default.
• W101067898 cites W2134234269 @default.
• W101067898 cites W2147339810 @default.
• W101067898 cites W2150575159 @default.
• W101067898 cites W2161859073 @default.
• W101067898 cites W2162740029 @default.
• W101067898 cites W2163552793 @default.
• W101067898 cites W2164452916 @default.
• W101067898 cites W2165948908 @default.
• W101067898 cites W2168301815 @default.
• W101067898 cites W2171038529 @default.
• W101067898 cites W2415535644 @default.
• W101067898 cites W74639727 @default.
• W101067898 cites W2157624452 @default.
• W101067898 doi "https://doi.org/10.2147/ott.s42858" @default.
• W101067898 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3638713" @default.
• W101067898 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23637543" @default.
• W101067898 hasPublicationYear "2013" @default.
• W101067898 type Work @default.
• W101067898 sameAs 101067898 @default.
• W101067898 citedByCount "3" @default.
• W101067898 countsByYear W1010678982016 @default.
• W101067898 countsByYear W1010678982017 @default.
• W101067898 crossrefType "journal-article" @default.
• W101067898 hasAuthorship W101067898A5000481700 @default.
• W101067898 hasAuthorship W101067898A5011572479 @default.
• W101067898 hasAuthorship W101067898A5021302353 @default.
• W101067898 hasAuthorship W101067898A5036896389 @default.
• W101067898 hasAuthorship W101067898A5037010363 @default.
• W101067898 hasAuthorship W101067898A5040401045 @default.
• W101067898 hasAuthorship W101067898A5048224285 @default.
• W101067898 hasAuthorship W101067898A5048601363 @default.
• W101067898 hasAuthorship W101067898A5052105775 @default.
• W101067898 hasAuthorship W101067898A5054922325 @default.
• W101067898 hasAuthorship W101067898A5058656430 @default.
• W101067898 hasAuthorship W101067898A5072732975 @default.
• W101067898 hasAuthorship W101067898A5089701217 @default.

• next